Did you know that CDK4/6 inhibitors (Ibrance®, palbociclib; Verzenio®, abemaciclib; Kisqali®, ribociclib) in combination with hormone therapy have revolutionized the treatment of HR+ HER2-metastatic breast cancer? Treatment with these survival extending drugs, has prompted rapid uptake in the US, EU and Japan since their first approvals in 2015 (US), 2016 (EU), and 2017 (JP), while China has yet to significantly adopt with first approval only in 2018. While CDK4/6 inhibitors are at different stages of global adoption, they are indisputably the new standard of care bringing better outcomes to patients with HR+HER2- metastatic breast cancer!

Source: CancerMPac®